Having trouble accessing articles? Reset your cache.

Eteplirsen: Additional Phase IIb data

Additional data from 10 patients aged 7-13 with DMD in the modified intent-to-treat (mITT) population of the open-label Study 4658-US-202 extension of the double-blind, U.S. Phase IIb Study 4658-US-201 trial showed that patients who received either dose of eteplirsen for 74 weeks (30 or 50 mg/kg) had a 2.2 m reduction in mean 6MWT

Read the full 542 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE